Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$9.04M, compared with $56.54M a year earlier. Trailing-twelve-month net income was -$43.21M.
Context
- Net income amounted to 32.0% of revenue in FY2025.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$42.23M (-288.8%) for the fiscal year ending Dec 2026, a slowdown from the +132.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.04M-40.2% QoQ
- Last fiscal yearDec 2025
- $22.37M+132.1% YoY
- LTMMar 2026
- -$43.21M-948.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -116.0% | +6.2% | +122.1 pp |
| 1 year | +132.1% | -288.8% | -420.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 22.37M USD
- Year-over-year change
- +132.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.37M | +132.1% |
| FY2024 | 2024-12-31 | (69.68M) | +15.5% |
| FY2023 | 2023-12-31 | (82.44M) | +9.6% |
| FY2022 | 2022-12-31 | (91.17M) | +27.4% |
| FY2021 | 2021-12-31 | (125.6M) | — |
Net Income vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -948.8% is the lowest of 11, against a peer median of -10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Mar 2026 | $133.22M USD | -9.9% | +14.2% | 1189.1% | |
| LTM Mar 2026 | $84.74M USD | -216.1% | +23.4% | 143627.1% | |
| LTM Mar 2026 | $83.01M USD | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $75.32M USD | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $69.87M USD | +152.1% | +61.9% | — | |
| LTM Mar 2026 | $66.14M USD | +249.7% | — | 454.9% | |
| LTM Mar 2026 | $61.98M USD | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $54.44M USD | -11.9% | +3.5% | — | |
| LTM Mar 2026 | $43.21M USD | -948.8% | — | — | |
| LTM Mar 2026 | $8.38M USD | -42.0% | -24.3% | 16.4% | |
| Peer median (excluding BDTX) | — | -10.9% | +3.5% | 822.0% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| Deferred Income Tax | 2.18M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.04M | 12.2M | 9.6M | 10.63M | 6.63M |
| Change in Working Capital | 7.02M | (9.9M) | 3.69M | (2.69M) | (8.73M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (2.23M) | 597K | 1.68M | (3.43M) |
| Other Working Capital | 5.45M | (7.67M) | 3.09M | (4.38M) | (5.3M) |
| Other Non-Cash Items | 2.01M | 3.28M | 2M | (905K) | 9.02M |
| Operating Cash Flow | (100.15M) | (85.08M) | (66.72M) | (62.3M) | 29.61M |
| Capital Expenditures | (2.71M) | (192K) | (33K) | 0 | 0 |
| Acquisitions (Net) | 2.7M | 9K | 0 | 94K | 27K |
| Purchases of Investments | (49.51M) | (60.14M) | (61.89M) | (122.88M) | (164.03M) |
| Sales of Investments | 182.83M | 113.69M | 78.17M | 139.75M | 119.02M |
| Other Investing Activities | (2.7M) | 0 | 95K | 0 | 74K |
| Investing Cash Flow | 130.61M | 53.37M | 16.35M | 16.97M | (44.91M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 729K | 177K | 71.85M | 24.49M | (146K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 82K | 1.05M | 0 |
| Financing Cash Flow | 729K | 177K | 71.93M | 25.55M | (146K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 31.19M | (31.54M) | 21.56M | (19.79M) | (15.44M) |
| Free Cash Flow | (102.86M) | (85.27M) | (66.75M) | (62.3M) | 29.61M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.